23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer
30 nov. 2021 09h15 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R....
23andMe Announces Redemption of All Outstanding Warrants
22 nov. 2021 16h15 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it will redeem all of its...
23andMe Reports FY2022 Second Quarter Financial Results
10 nov. 2021 16h05 HE
|
23andMe Holding Co.
Second quarter revenue of $55 millionRecent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE,...
23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders
03 nov. 2021 16h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe Announces the Closing of its Acquisition of Lemonaid Health
01 nov. 2021 16h05 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its...
23andMe Agrees to Acquire Lemonaid Health
22 oct. 2021 06h55 HE
|
23andMe, Inc.
Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives 23andMe to host investor webcast today at...
23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021
20 oct. 2021 18h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe to Present at the Wells Fargo Healthcare Conference
01 sept. 2021 16h05 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that management will be...
23andMe Reports FY2022 First Quarter Financial Results
13 août 2021 07h00 HE
|
23andMe, Inc.
First quarter revenue up 23% over prior yearStrong cash balance of $770 millionContinuing to advance therapeutics portfolio to drive future revenue growth SUNNYVALE, Calif., Aug. 13, 2021 ...
23andMe to Report FY2022 First Quarter Financial Results
29 juil. 2021 07h00 HE
|
23andMe, Inc.
SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...